PT - JOURNAL ARTICLE AU - Veeru Kasivisvanathan AU - Jamie Lindsay AU - Sara Rakshani-Moghadam AU - Ahmed Elhamshary AU - Konstantinos Kapriniotis AU - Georgios Kazantzis AU - Bilal Syed AU - John Hines AU - Axel Bex AU - Daniel Heffernan Ho AU - Martin Hayward AU - Chetan Bhan AU - Nicola MacDonald AU - Simon Clarke AU - David Walker AU - Geoff Bellingan AU - James Moore AU - Jennifer Rohn AU - Asif Muneer AU - Lois Roberts AU - Fares Haddad AU - John D Kelly AU - UCLH study group collaborators TI - Evaluation of 30-day mortality for 500 patients undergoing non-emergency surgery in a COVID-19 cold site within a multicentre regional surgical network during the COVID-19 pandemic AID - 10.1101/2020.06.10.20115543 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.10.20115543 4099 - http://medrxiv.org/content/early/2020/06/12/2020.06.10.20115543.short 4100 - http://medrxiv.org/content/early/2020/06/12/2020.06.10.20115543.full AB - Background Two million non-emergency surgeries are being cancelled globally every week due to the COVID-19 pandemic, which will have a major impact on patients and healthcare systems.Objective To determine whether it is feasible and safe to continue non-emergency surgery in the COVID-19 pandemicDesign, setting and participants This is a cohort study of 500 consecutive patients undergoing non-emergency surgery in a dedicated COVID-19 cold site following the first case of COVID-19 that was reported in the institution. The study was carried out during the peak of the pandemic in the United Kingdom, which currently has one of the highest number of cases and deaths from COVID-19 globally.We set up a hub-and-spoke surgical network amongst 14 National Health Service institutions during the pandemic. The hub was a cancer centre, which was converted into a COVID-19 cold site, performing urological, thoracic, gynaecological and general surgical operations.Outcomes The primary outcome was 30-day mortality from COVID-19. Secondary outcomes included all-cause mortality and post-operative complications at 30-days.Results 500 patients underwent surgery with median age 62.5 (IQR 51-71). 65% were male and 60% had a known diagnosis of cancer. 44% of surgeries were performed with robotic or laparoscopic assistance and 61% were considered complex or major operations.None of the 500 patients undergoing surgery died from COVID-19 at 30-days. 30-day allcause mortality was 3/500 (1%). 10 (2%) patients were diagnosed with COVID-19, 4 (1%) with confirmed laboratory diagnosis and 6 (1%) with probable COVID-19. 33/500 (7%) of patients developed Clavien-Dindo grade 3 or higher complications, with 1/33 (3%) occurring in a patient with COVID-19.Conclusion It is safe to continue non-emergency surgery during the COVID-19 pandemic with appropriate service reconfiguration.Patient summary No patients died from COVID-19 when undergoing non-emergency surgery during the pandemic in one of the worst affected world regions.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis was not a clinical trial.Funding StatementNo direct study funding was received. However we would like to acknowledge: Veeru Kasivisvanathan is an Academic Clinical Lecturer funded by the United Kingdom National Institute for Health Research (NIHR). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board at University College London Hospital deemed this work to be exempt from ethical approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available upon reasonable request from bona fide researchers.